185 related articles for article (PubMed ID: 25905781)
21. Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies.
Wang JW; Jagu S; Kwak K; Wang C; Peng S; Kirnbauer R; Roden RB
Virology; 2014 Jan; 449():304-16. PubMed ID: 24418565
[TBL] [Abstract][Full Text] [Related]
22. Monoclonal antibodies recognizing cross-neutralization epitopes in human papillomavirus 16 minor capsid protein L2.
Nakao S; Mori S; Kondo K; Matsumoto K; Yoshikawa H; Kanda T
Virology; 2012 Dec; 434(1):110-7. PubMed ID: 23051711
[TBL] [Abstract][Full Text] [Related]
23. Human papillomavirus type 58 L1 virus-like particles purified by two-step chromatography elicit high levels of long-lasting neutralizing antibodies.
Xie X; Liu Y; Zhang T; Xu Y; Bao Q; Chen X; Liu H; Xu X
Arch Virol; 2013 Jan; 158(1):193-9. PubMed ID: 22965579
[TBL] [Abstract][Full Text] [Related]
24. Immunization of mice by a multimeric L2-based linear epitope (17-36) from HPV type 16/18 induced cross reactive neutralizing antibodies.
Khiavi FM; Arashkia A; Nasimi M; Mahdavi M; Golkar M; Roohvand F; Azadmanesh K
Res Pharm Sci; 2017 Aug; 12(4):265-273. PubMed ID: 28855937
[TBL] [Abstract][Full Text] [Related]
25. The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies.
Rubio I; Seitz H; Canali E; Sehr P; Bolchi A; Tommasino M; Ottonello S; Müller M
Virology; 2011 Jan; 409(2):348-59. PubMed ID: 21074234
[TBL] [Abstract][Full Text] [Related]
26. Human papillomavirus vaccines.
Breitburd F; Coursaget P
Semin Cancer Biol; 1999 Dec; 9(6):431-44. PubMed ID: 10712890
[TBL] [Abstract][Full Text] [Related]
27. Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types.
Rizk RZ; Christensen ND; Michael KM; Müller M; Sehr P; Waterboer T; Pawlita M
J Gen Virol; 2008 Jan; 89(Pt 1):117-129. PubMed ID: 18089735
[TBL] [Abstract][Full Text] [Related]
28. Adenovirus based HPV L2 vaccine induces broad cross-reactive humoral immune responses.
Vujadinovic M; Khan S; Oosterhuis K; Uil TG; Wunderlich K; Damman S; Boedhoe S; Verwilligen A; Knibbe J; Serroyen J; Schuitemaker H; Zahn R; Scheper G; Custers J; Vellinga J
Vaccine; 2018 Jul; 36(30):4462-4470. PubMed ID: 29914845
[TBL] [Abstract][Full Text] [Related]
29. HPV11 mutant virus-like particles elicit immune responses that neutralize virus and delineate a novel neutralizing domain.
Ludmerer SW; McClements WL; Wang XM; Ling JC; Jansen KU; Christensen ND
Virology; 2000 Jan; 266(2):237-45. PubMed ID: 10639310
[TBL] [Abstract][Full Text] [Related]
30. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
[TBL] [Abstract][Full Text] [Related]
31. Identification and characterization of a cross-neutralization epitope of Enterovirus 71.
Liu CC; Chou AH; Lien SP; Lin HY; Liu SJ; Chang JY; Guo MS; Chow YH; Yang WS; Chang KH; Sia C; Chong P
Vaccine; 2011 Jun; 29(26):4362-72. PubMed ID: 21501643
[TBL] [Abstract][Full Text] [Related]
32. Identification of the mimotopes within the major capsid protein L1 of human papillomavirus types 18 and 45, using neutralizing monoclonal antibodies.
Li N; Zhang G; Chen Y; Zhou J; Hui C; Li S; Liu H; Liu Y; Qi Y; Wang A
Int J Biol Macromol; 2021 Mar; 174():587-595. PubMed ID: 33493568
[TBL] [Abstract][Full Text] [Related]
33. Human papillomavirus 16L1-58L2 chimeric virus-like particles elicit durable neutralizing antibody responses against a broad-spectrum of human papillomavirus types.
Chen X; Liu H; Wang Z; Wang S; Zhang T; Hu M; Qiao L; Xu X
Oncotarget; 2017 Sep; 8(38):63333-63344. PubMed ID: 28968993
[TBL] [Abstract][Full Text] [Related]
34. Interactions between papillomavirus L1 and L2 capsid proteins.
Finnen RL; Erickson KD; Chen XS; Garcea RL
J Virol; 2003 Apr; 77(8):4818-26. PubMed ID: 12663788
[TBL] [Abstract][Full Text] [Related]
35. Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine.
Jagu S; Kwak K; Schiller JT; Lowy DR; Kleanthous H; Kalnin K; Wang C; Wang HK; Chow LT; Huh WK; Jaganathan KS; Chivukula SV; Roden RB
J Virol; 2013 Jun; 87(11):6127-36. PubMed ID: 23536682
[TBL] [Abstract][Full Text] [Related]
36. Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate.
Nieto K; Weghofer M; Sehr P; Ritter M; Sedlmeier S; Karanam B; Seitz H; Müller M; Kellner M; Hörer M; Michaelis U; Roden RB; Gissmann L; Kleinschmidt JA
PLoS One; 2012; 7(6):e39741. PubMed ID: 22761884
[TBL] [Abstract][Full Text] [Related]
37. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.
Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909
[TBL] [Abstract][Full Text] [Related]
38. Broadly neutralizing antiviral responses induced by a single-molecule HPV vaccine based on thermostable thioredoxin-L2 multiepitope nanoparticles.
Spagnoli G; Pouyanfard S; Cavazzini D; Canali E; Maggi S; Tommasino M; Bolchi A; Müller M; Ottonello S
Sci Rep; 2017 Dec; 7(1):18000. PubMed ID: 29269879
[TBL] [Abstract][Full Text] [Related]
39. Crystal Structures of Two Immune Complexes Identify Determinants for Viral Infectivity and Type-Specific Neutralization of Human Papillomavirus.
Li Z; Wang D; Gu Y; Song S; He M; Shi J; Liu X; Wei S; Li J; Yu H; Zheng Q; Yan X; Baker TS; Zhang J; McLellan JS; Li S; Xia N
mBio; 2017 Sep; 8(5):. PubMed ID: 28951471
[TBL] [Abstract][Full Text] [Related]
40. A surface immunodeterminant of human papillomavirus type 16 minor capsid protein L2.
Kawana K; Matsumoto K; Yoshikawa H; Taketani Y; Kawana T; Yoshiike K; Kanda T
Virology; 1998 Jun; 245(2):353-9. PubMed ID: 9636375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
